Glycated albumin (GA) and inflammation: role of GA as a potential marker of inflammation
- 473 Downloads
Abnormal levels of glycated albumin (GA) are associated with the onset of both diabetes and inflammation. Although inflammation has long been associated with diabetes, this article aims to explore the underlying mechanisms of this relationship as it pertains to the role of GA.
We have reviewed 52 research articles since the year 2000. Common search terms used were “(inflammatory mediator) and GA” or “inflammation and GA”. The findings have been organized according to diabetic complications with respect to the interactions of GA and inflammatory mediators. Glycated albumin and specific inflammatory mediators have been reported to play various roles in the pathogenesis of insulin resistance, atherosclerosis, coronary artery disease, retinopathy, and nephropathy. In the case of nephropathy and recently retinopathy, there is considerable evidence for GA in concert with inflammation playing a direct role in organ pathology. There is copious literature detailing GA’s involvement in stimulating inflammatory markers and certain pro-inflammatory cytokines. A recent clinical study has shown GA to be a marker for inflammation in non-diabetic rheumatoid arthritis patients with the significance of standard inflammatory markers.
The clinical utility of GA measurement may likely reside in its versatility as both a mediator of inflammation as well as a marker to track hyperglycemia and other diabetes complications. Further understanding of the role GA plays in glycemic and inflammatory diseases could lead to its acceptance as an independent bio-inflammatory marker.
KeywordsInflammation Glycated albumin Inflammatory marker Glycated albumin point-of-care test
Dr. David Horwitz, Dr. Tessa Lebinger, Dr. Omar Ali, Dr. Salim Aziz, Dr. Saul Ship, and Dr. Alan Carter of the Epinex Diagnostics Inc. Science Advisory Board; Dr. David Trasoff, Tasnim Ahmed, and Kajal Bains of Epinex Diagnostics Inc.
- 11.Lu L, Pu L, Xu X, Zhang Q, Zhang R, Zhang J, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-α with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem. 2007. doi: 10.1016/j.clinbiochem.2007.03.022.Google Scholar
- 15.Bian Z. Signaling pathways for glycated human serum albumin-induced IL-8 and MCP-1 secretion in human RPE cells. Investig Ophthalmol Vis Sci. 2001;42(7):1660–8.Google Scholar
- 20.Mukai N, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, et al. Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama study. Cardiovasc Diabetol. 2015. doi: 10.1186/s12933-015-0247-7.PubMedPubMedCentralGoogle Scholar
- 22.Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS. Value of serum glycated albumin and high-sensitivity-C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2006. doi: 10.1186/1475-2840-5-27.PubMedPubMedCentralGoogle Scholar
- 45.Varghese A, Asha NS, Celine TM, Prasanna D. Inflammatory markers in type II diabetes mellitus. Pharm J. 2015;4(7):64–6.Google Scholar
- 49.Kate C, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol. 2002;71(3):1122–33.Google Scholar